Share

June 2017; 7 (3) Case

Restless legs syndrome with augmentation successfully treated with IV iron

Vincent LaBarbera, Lynn Marie Trotti, David Rye
First published June 29, 2016, DOI: https://doi.org/10.1212/CPJ.0000000000000276
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
190

Share

Article Information

vol. 7 no. 3 e26-e28
DOI: 
https://doi.org/10.1212/CPJ.0000000000000276
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received January 20, 2016
  • Accepted May 24, 2016
  • First Published June 29, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Vincent LaBarbera, MD,
    2. Lynn Marie Trotti, MD, MSc and
    3. David Rye, MD, PhD
  1. Vincent LaBarbera, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lynn Marie Trotti, MD, MSc and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) American Academy of Sleep Medicine, funding for travel to meetings other than CME (2) International Restless Legs Syndrome Study Group, funding for travel to researching meeting (other than CME)

    Editorial Boards:

    1. (1) Journal of Clinical Sleep Medicine, editorial board member, 2015-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH, NINDS, K23 NS083748, PI, 2014-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David Rye, MD, PhD
    4. Scientific Advisory Boards:

    1. Commercial: Xenoport; Jazz Pharmaceuticals; UCB Pharma Inc.; Flamel Technologies; Balance Therapeutics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. UCB Pharma Inc.; Xenoport; Jazz Pharmaceuticals

    Editorial Boards:

    1. SLEEP (Deputy Editor) Sleep Medicine (Editorial Board) Experimental Neurology (Editorial Board) Sleep Medicine Reviews (Editorial Board) Narcolepsy Network (Medical Advisory Board)

    Patents:

    1. International Patent Application No.: PCT/US2009/037034 - Methodology for pharmacological formulation for treatment of hypersomnia with GABA-A receptor antagonists including flumazenil.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. UCB Pharma, Jazz Pharmaceuticals, Xenoport Inc., Flamel Technologies, Balance Therapeutics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH - Role: PI. NS089719 ? Characterization of an endogenous GABA-ergic mechanism underlying hypersomnia. (07/01/2015- 6/31/2019).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (PCT/US2009/037034)- Methodology for pharmacological formulation for treatment of hypersomnia with GABA-A receptor antagonists including flumazenil. Technology/invention purchased from Emory University in 2015 - first royalty payment received by D. Rye calendar year 2016 from Balance Therapeutics Inc.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Emory University School of Medicine, Atlanta, GA.
  1. Correspondence to:
    lbecke2{at}emory.edu
View Full Text

Article usage

Article usage: June 2016 to August 2023

AbstractFullPdfSource
Jun 2016901Highwire
Jul 20163501Highwire
Aug 20161801Highwire
Sep 20162001Highwire
Oct 20161900Highwire
Nov 20161700Highwire
Dec 2016602Highwire
Jan 20173001Highwire
Feb 20172601Highwire
Mar 20171300Highwire
Apr 20172200Highwire
May 20171102Highwire
Jun 20175461725Highwire
Jul 2017371311Highwire
Aug 201725957Highwire
Sep 201712303Highwire
Oct 20173100Highwire
Nov 20173723Highwire
Dec 20174535Highwire
Jan 20186333Highwire
Feb 20184922Highwire
Mar 20182514Highwire
Apr 20185724Highwire
May 20186302Highwire
Jun 201815603Highwire
Jun 201841212pmc
Jul 20189502Highwire
Aug 20184104Highwire
Aug 2018488pmc
Sep 201813011Highwire
Oct 20184512Highwire
Nov 20184013Highwire
Dec 20185513Highwire
Jan 20192904Highwire
Feb 20194003Highwire
Mar 20193603Highwire
Apr 20191703Highwire
May 20192403Highwire
Jun 20191501Highwire
Jul 20192025Highwire
Aug 20192101Highwire
Sep 20193001Highwire
Oct 20191926Highwire
Nov 20191602Highwire
Dec 20192511Highwire
Jan 20203002Highwire
Feb 20202103Highwire
Mar 20201200Highwire
Apr 2020600Highwire
May 20201200Highwire
Jun 2020913Highwire
Jul 20201200Highwire
Aug 20201000Highwire
Sep 20201101Highwire
Oct 2020500Highwire
Nov 20201600Highwire
Dec 2020801Highwire
Jan 20211401Highwire
Feb 20212100Highwire
Mar 20212700Highwire
Apr 2021600Highwire
May 20212200Highwire
Jun 20211200Highwire
Jul 20211800Highwire
Aug 20213110Highwire
Sep 20211700Highwire
Oct 20212301Highwire
Nov 2021300Highwire
Dec 20211100Highwire
Jan 20222801Highwire
Feb 20222600Highwire
Mar 20221200Highwire
Apr 2022800Highwire
May 20221201Highwire
Jun 2022510Highwire
Jul 2022603Highwire
Aug 20221800Highwire
Sep 20221601Highwire
Oct 20222402Highwire
Nov 20224003Highwire
Dec 20221501Highwire
Jan 20232401Highwire
Feb 20231202Highwire
Mar 20231001Highwire
Apr 20231201Highwire
May 20231200Highwire
Jun 2023701Highwire
Jul 20231800Highwire
Aug 2023400Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles